Valley Fever Market Information, by Types of Treatments (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Others) by Site of Infection (Skin, Liver, Bones, Heart, Brain, Membranes That Surround the Brain and Spinal Cord, Others) - Forecast to 2030

Valley Fever Market Analysis

The valley fever market is expected to reach USD 256.5 Million by 2030 at 4.6% CAGR during the forecast period 2022-2030. The rising geriatric population who have higher chances of infection is generating a huge demand for treatment drugs for this disease.

Valley fever is a disease caused by the fungus of the genus coccidioides under the family Onagraceae. The disease-causing fungal pathogens live in the soil and people inhaling the fungal spores may get infected. The spores of these fungi get released in the atmosphere even with slight disturbance in soil and conditions like windstorms may cause epidemics in the far-flung areas too. Valley Fever is endemic in some parts of the USA and is also found in South America and Mexico. The initial symptoms of this disease are mild and those are similar to other flues like pneumonia and bronchitis. However, people with suppressed immune systems are more prone to the disease.

The changing lifestyle and weakening of the human immune system are the major causes for the rising incidence of these diseases. The USA's Center for Disease Control & Prevention has called this disease a silent epidemic as there are no prominent visible systems and therefore the reporting of this disease is very low. It is difficult to prevent the disease as the fungal spores, known as Arthroconidia, are abundantly available in air dust. Antifungal drugs like fluconazole, Amphotericin B, itraconazole, ketoconazole, etc. have been advocated for the treatment of chronic cases. Moreover, this disease is also reported in cattle and other domestic animals but they are non-zoonotic. The frequent incidences of the disease are pushing medical research organizations to develop specific treatment procedures.

Covid 19 Analysis

Covid-19 pandemic negatively affected the global valley fever market. Covid fear and the high number of covid cases led to the overburdening of the health system which was unable to focus on other milder diseases. Therefore, the reporting of incidents of coccidioidomycosis went low and so did the treatment rate. During the pandemic, the pharmaceutical industry began focusing on covid drugs which affected the production of other drugs including antifungal drugs for the treatment of valley fever. 

Valley Fever Market Dynamics

Drivers

The rising incidence of coccidioidomycosis in the elderly population due to declining immune strength and change in lifestyle is driving the growth of the global valley fever market. With improvement in literacy rate, the awareness about this disease has also increased substantially. Therefore, more people are coming out for testing and treatment of the disease. The disease incidence in cattle is also increasing which will contribute to the market growth but at the same time, it is also a cause of concern. The improvements in public health infrastructure for the treatment of disease are also largely contributing to the strengthening of the market. Moreover, the developments in vaccine technology and pharmaceutical drugs will bring brighter prospects for the valley fever market.

Restraints

Though the rising incidence of the disease is contributing to the valley fever market growth, it is also a matter of serious concern. The frequent cases of incidence on cattle may also burden the health system. Moreover, the presence of herbal and home remedies acts as major restraints to valley fever market growth. The poor health infrastructure in many countries and the high price for diagnosis and treatment are other major growth-inhibiting factors.

Valley fever, also known as coccidioidomycosis, is a mammalian fungal disease caused by infection of the fungus coccidioides. Two fungi namely, Coccidioides immitis and Coccidioides posadasii, are primarily responsible for the disease. These fungi are soil-borne and readily infect people having weak immune systems. Coccidioidomycosis is endemic in certain parts of the US and is commonly found in some parts of Central and South America.

Valley Fever is a mild disease and more than 60% of the people suffering from this do not show any symptoms while the rest have symptoms similar to pneumonia and bronchitis. The common symptoms are feeling of tiredness, fever, muscle pain, joint pain, fatigue, cough, and also loss of smell and taste. However, Valley Fever is not contagious and only in some cases becomes chronic. This disease can be diagnosed through blood tests and tests of other body fluids. Doctors generally recommend antifungal drugs in case of severe infections but many patients get better with home treatment too.

Study Objectives

The specific objectives of this market report on the global Valley fever market are given below:

• To provide a complete overview of the global Valley fever market.


• To analyze and forecast the market in terms of value and volume.


• To visualize the impact of the covid 19 pandemic on the market growth.


• To project the market dynamics including the problems and prospects of the market.


• To provide technical details of products for gaining deep knowledge about the market.


• To provide an overview of the regional market and other market segments.


• To give details about the competitive landscape and key market players.

Valley Fever Market Segment Analysis

Market segmentation, By Types of Treatments

• Fluconazole


• Itraconazole


• Voriconazole


• Posaconazole


• Others

Fluconazole holds the major market share as it is one of the most effective treatments against valley fever and other similar fungal pathogens. The low price of the drug is also a major contributing factor to its demand and market growth.

Market segmentation, By Site of Infection

• Skin


• Lungs


• Liver


• Bones


• Heart


• Brain


• Membranes that Surround the Brain and Spinal Cord


• Others

Lungs are the most affected organs as this fungus affects the respiratory system the most. However, some of the symptoms like rashes also do occur in the skin.

By end-use, the market is divided into

• Human


• Cattle


• Sheep and goats


• Camel


• Others

Humans are the frequent sufferers of this disease and require more treatment than other mammals. This disease in livestock is very mild and often requires no treatment.

Valley Fever Market Regional Analysis

The different regional markets for the global Valley fever market are:

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  • Mexico
  
  
  
  

• South America
  
  
  
  • Brazil
  
  
  • Argentina
  
  
  
  

• Europe
  
  
  
  • UK
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • China
  
  
  • India
  
  
  • Japan
  
  
  • Australia & New Zealand
  
  
  • Rest of Asia-Pacific
  
  
  
  

• Rest of the world ( RoW )
  
  
  
  • The Middle East
  
  
  • Africa
  
  
  
  

Among different regions, North America holds the largest Market share as this disease is endemic to this region. The frequent incidence of viral fever leads to the high market demand for the treatment process. According to the Centers for Disease Control & Prevention CDC, the USA alone reported 18,407 cases of coccidioidomycosis in 2019. Moreover, good health infrastructure here is also supporting the market growth.

Latin America follows next to North America in the number of cases. Coccidioidomycosis has been reported sporadically in countries like Mexico, Colombia, Venezuela, Brazil, and Paraguay. The incidence of this disease is also being reported in some Asian countries but it is not prevalent in this region.

Valley Fever Market Competitive Landscape

The major global companies playing a key role in the viral fever market are :

• Novartis


• Anacor Pharmaceuticals


• Johnson and Johnson


• Valeant Pharmaceutical


• Bristol Meyer Squibb


• GlaxoSmithKline Pharmaceuticals Limited


• Galderma S.A.


• Pfizer Inc.

Recent Developments

• In December 2019, UC Berkeley School of Public Health, A premier health Research Institute in California, announced the launch of new major research initiatives to tackle valley fever. A 5-year grant of 3.8 million USD is being provided by the National Institute of Health (NIH) for conducting the research.

Intended Audience

This report will be beneficial for every stakeholder of the Valley fever market such as :

• Manufacturers of Valley Fever Drugs


• Antifungal drug manufacturing companies


• Suppliers and Distributors


• Pharmaceutical and Biotechnology companies


• Hospitals and laboratories


• Research institutes


• End users

Valley Fever Market Report Overview

This report from Market Research Future provides an in-depth analysis of the Valley fever market. This report covers both qualitative and quantitative aspects of the market including future projections. Moreover, the technological analysis section of this report gives clear information about the products and processes to help in a better understanding of the market. Furthermore, this report contains a detailed performance-based analysis of all the market segments. This report has also highlighted the key players and the current developments in the Valley fever market. Additionally, Covid-19 analysis has also been added to the report to study the impact of the pandemic on the market.